Elobixibat

Elobixibat is an inhibitor of the sodium/bile acid and sulfated solute cotransporter (ASBT), also known as the ileal bile acid transporter (IBAT, IC50s = 0.53, 0.13, and 5.8 nM for the human, mouse, and canine transporters, respectively). It is selective for ASBT over the hepatic sodium/bile acid cotransporter (IC50 = 240 nM). Elobixibat induces mild giant migrating contractions in the colon and increases the number of defecations in conscious dogs two hours after administration of 3, 10, or 30 mg/kg doses, as well as increases the number of defecations after ten hours at 30 mg/kg. Oral administration of elobixibat (1.2 mg/kg per day) reduces methionine- and choline-deficient diet-induced increases in serum bile acid levels and hepatic inflammation, fibrosis, and cytokine gene expression in a mouse model of non-alcoholic steatohepatitis (NASH). Formulations containing elobixibat have been used in the treatment of chronic constipation.Formal Name: (2R)-N-[2-[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-glycine. CAS Number: 439087-18-0. Synonyms: A3309, AZD 7806. Molecular Formula: C36H45N3O7S2. Formula Weight: 695.9. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMSO: Sparingly soluble: 1-10 mg/ml, Methanol: Soluble. SMILES: O=C(O)CNC([C@@H](C1=CC=CC=C1)NC(COC2=C(SC)C=C(C3=C2)N(C4=CC=CC=C4)CC(CS3(=O)=O)(CCCC)CCCC)=O)=O. InChi Code: InChI=1S/C36H45N3O7S2/c1-4-6-18-36(19-7-5-2)24-39(27-16-12-9-13-17-27)28-20-30(47-3)29(21-31(28)48(44,45)25-36)46-23-32(40)38-34(26-14-10-8-11-15-26)35(43)37-22-33(41)42/h8-17,20-21,34H,4-7,18-19,22-25H2,1-3H3,(H,37,43)(H,38,40)(H,41,42)/t34-/m1/s1. InChi Key: XFLQIRAKKLNXRQ-UUWRZZSWSA-N.